Telix Pharmaceuticals (ASX: TLX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Telix Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Telix Pharmaceuticals (ASX: TLX)
Latest News
Share Fallers
Why did the Telix share price just plunge 18%?
Growth Shares
3 fantastic ASX 200 growth shares to buy with $2,000 in August
Healthcare Shares
Why this $7 billion ASX 200 healthcare share is now trading at a discount
Share Market News
CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August
Broker Notes
9 ASX 200 shares attracting 'strong buy' ratings from the experts
Broker Notes
These ASX 200 shares could rise 12% to 60%
Healthcare Shares
Why did the Telix share price just crash 16%?
Growth Shares
3 ASX growth shares with 10-year compounding potential
Healthcare Shares
JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?
Growth Shares
The ultimate Australian stocks to buy and hold for 10+ years
Broker Notes
Bell Potter says this growing ASX 200 stock can rise over 40%
Share Market News
5 things to watch on the ASX 200 on Friday
Frequently Asked Questions
-
No, Telix does not pay dividends at this time.
-
Telix Pharmaceuticals Ltd listed on the ASX on 15 November 2017.
TLX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Telix Pharmaceuticals
Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe.
The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States.
